Patents and Trademarks
Acura actively pursues patents and trademark protection for our business interests. Except for those rights conferred in the King Agreement, Acura has retained all intellectual property rights to our technologies and related product candidates. We encourage you to refer to the Risk Factors link on this web site and contained in our filings with the Securities and Exchange Commission for a discussion of, among other things, the effect pending patent applications owned by third parties would have on our business if issued.
Issued Patents
| Patent Number | Jurisdiction | Allowed Claims | General Subject |
|---|---|---|---|
| 7,201,920 | U.S. | 54 | Compositions including an opioid intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. We believe the 920 Patent encompasses all of our opioid analgesic product candidates currently in development. |
| 7,510,726 | U.S. | 20 | Compositions including an opioid and an expanded list (compared to the 920 patent) of functional inactive ingredients intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. A third party has asserted an interference claim against a 21st claim in our original patent application that has been subsequently withdrawn. |
| 7,476,402 | U.S. | 18 | Compositions including kappa and mu opioid receptor agonists intended to deter opioid analgesic product misuse and abuse. |
Pending Patents
Acura has numerous U.S. non-provisional pending patent applications and multiple international patent applications filed relating to compositions containing abuseable active pharmaceutical ingredients and abuse deterrent ingredients.
Trademarks
Acuracet®, Acurox®, Aversion®, Impede™, Tramavert®, Vycavert® and Acura Pharmaceuticals® are trademarks of Acura Pharmaceuticals, Inc.
